{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:42:59Z","timestamp":1787064179183,"version":"build-2736575974"},"reference-count":57,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.aohep.2022.100738","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T03:31:56Z","timestamp":1656646316000},"page":"100738","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Safety and efficacy of dyslipidemia treatment in NAFLD patients: a meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"27","author":[{"given":"Mohamed","family":"Abdallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Landon","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Provenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raseen","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smitha","family":"Gowda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwani K.","family":"Singal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.aohep.2022.100738_bib0001","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease\u2013Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.aohep.2022.100738_bib0002","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","article-title":"Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States","volume":"148","author":"Wong","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2022.100738_bib0003","doi-asserted-by":"crossref","DOI":"10.1097\/TP.0000000000000048","article-title":"Evolving frequency and outcomes of simultaneous liver kidney transplants based on liver disease etiology","author":"Singal","year":"2014","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.aohep.2022.100738_bib0004","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/lt.25443","article-title":"NASH is the most rapidly growing etiology for acute-on-chronic liver failure-related hospitalization and disease burden in the United States\u2013A population-based study","volume":"25","author":"Axley","year":"2019","journal-title":"Liver Transpl"},{"issue":"4","key":"10.1016\/j.aohep.2022.100738_bib0005","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.cgh.2018.05.057","article-title":"Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2022.100738_bib0006","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ecl.2015.09.002","volume":"45","author":"Adhyaru","year":"2016","journal-title":"Endocrinol Metab Clin N Am"},{"issue":"11","key":"10.1016\/j.aohep.2022.100738_bib0007","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.2174\/138161212799504803","article-title":"Statins as anti-inflammatory agents in atherogenesis\u2013Molecular mechanisms and lessons from the recent clinical trials","volume":"18","author":"Antonopoulos","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.aohep.2022.100738_bib0008","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2019-318237","article-title":"Cirrhosis as new indication for statins","author":"Bosch","year":"2020","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.aohep.2022.100738_bib0009","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/hep.20671","article-title":"Statins and hepatotoxicity\u2013Focus on patients with fatty liver","volume":"41","author":"Chalasani","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2022.100738_bib0010","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.aohep.2022.100738_bib0011","doi-asserted-by":"crossref","DOI":"10.1177\/0962280219889080","article-title":"Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis","author":"McGrath","year":"2020","journal-title":"Stat Methods Med Res"},{"issue":"6","key":"10.1016\/j.aohep.2022.100738_bib0012","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.aohep.2022.100738_bib0013","series-title":"Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis","author":"Deeks","year":"2005"},{"issue":"7","key":"10.1016\/j.aohep.2022.100738_bib0014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses\u2013The PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"10","key":"10.1016\/j.aohep.2022.100738_bib0015","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/j.1365-2036.2007.03307.x","article-title":"Review article\u2013Drug hepatotoxicity","volume":"25","author":"Chang","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.aohep.2022.100738_bib0016","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1592\/phco.24.6.584.34738","article-title":"Statins and liver toxicity\u2013A meta-analysis","volume":"24","author":"de Denus","year":"2004","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.aohep.2022.100738_bib0017","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1592\/phco.28.4.522","article-title":"Safety of statin therapy in patients with preexisting liver disease","volume":"28","author":"Onofrei","year":"2008","journal-title":"Pharmacotherapy"},{"issue":"8","key":"10.1016\/j.aohep.2022.100738_bib0018","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.cgh.2018.04.023","article-title":"Treatment of dyslipidemia in common liver diseases","volume":"16","author":"Speliotes","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.aohep.2022.100738_bib0019","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/17425255.2018.1483337","article-title":"Peroxisome proliferator-activated receptor alpha-mediated drug toxicity in the liver","volume":"14","author":"Hedrington","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"12","key":"10.1016\/j.aohep.2022.100738_bib0020","first-page":"1063","article-title":"[A meta-analysis on the safety of combination therapy with fenofibrate and statins]","volume":"41","author":"Geng","year":"2013","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"issue":"2","key":"10.1016\/j.aohep.2022.100738_bib0021","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/j.gastro.2014.04.046","article-title":"No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial","volume":"147","author":"Sanyal","year":"2014","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.aohep.2022.100738_bib0022","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/hep.27289","article-title":"Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease\u2013Results from the Welcome* study","volume":"60","author":"Scorletti","year":"2014","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"3","key":"10.1016\/j.aohep.2022.100738_bib0023","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2015.05.006","article-title":"Statin use and non-alcoholic steatohepatitis in at risk individuals","volume":"63","author":"Dongiovanni","year":"2015","journal-title":"J Hepatol"},{"issue":"25","key":"10.1016\/j.aohep.2022.100738_bib0024","doi-asserted-by":"crossref","first-page":"7860","DOI":"10.3748\/wjg.v21.i25.7860","article-title":"Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome","volume":"21","author":"Kargiotis","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.aohep.2022.100738_bib0025","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030671","article-title":"Statin use and the risk of hepatocellular carcinoma\u2013A meta-analysis of observational studies","volume":"12","author":"Islam","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.aohep.2022.100738_bib0026","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.aohep.2022.100738_bib0027","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jceh.2019.07.008","article-title":"Extra-hepatic manifestations of nonalcoholic fatty liver disease\u2013A review","volume":"10","author":"Tariq","year":"2020","journal-title":"J Clin Exp Hepatol"},{"issue":"8","key":"10.1016\/j.aohep.2022.100738_bib0028","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3109\/07853890.2010.518623","article-title":"Meta-analysis\u2013Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity","volume":"43","author":"Musso","year":"2011","journal-title":"Ann Med"},{"issue":"6","key":"10.1016\/j.aohep.2022.100738_bib0029","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s11886-012-0313-7","article-title":"Dyslipidemias in the prevention of cardiovascular disease\u2013Risks and causality","volume":"14","author":"Graham","year":"2012","journal-title":"Curr Cardiol Rep"},{"issue":"8","key":"10.1016\/j.aohep.2022.100738_bib0030","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.metabol.2016.05.003","article-title":"Non-alcoholic fatty liver disease and dyslipidemia\u2013An update","volume":"65","author":"Katsiki","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.aohep.2022.100738_bib0031","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1476-511X-13-100","article-title":"Nonalcoholic steatohepatitis is associated with an atherogenic lipoprotein subfraction profile","volume":"13","author":"Corey","year":"2014","journal-title":"Lipids Health Disease"},{"issue":"9756","key":"10.1016\/j.aohep.2022.100738_bib0032","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","article-title":"Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study\u2013A post-hoc analysis","volume":"376","author":"Athyros","year":"2010","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.aohep.2022.100738_bib0033","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1016\/j.ijcard.2013.06.024","article-title":"Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels","volume":"168","author":"Tikkanen","year":"2013","journal-title":"Int J Cardiol"},{"issue":"10","key":"10.1016\/j.aohep.2022.100738_bib0034","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/hep4.1241","article-title":"Among patients with NAFLD, treatment of dyslipidemia does not reduce cardiovascular mortality","volume":"2","author":"Shahab","year":"2018","journal-title":"Hepatol Commun"},{"issue":"1","key":"10.1016\/j.aohep.2022.100738_bib0035","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S2468-1253(19)30320-6","article-title":"Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY)\u2013A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"5","author":"Pose","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2022.100738_bib0036","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jhep.2018.07.019","article-title":"Statins\u2013Old drugs as new therapy for liver diseases?","volume":"70","author":"Pose","year":"2019","journal-title":"J Hepatol"},{"issue":"3 Suppl","key":"10.1016\/j.aohep.2022.100738_bib0037","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jacl.2014.02.011","article-title":"The National Lipid Association's Statin Safety Task F. An assessment by the statin liver safety task force\u20132014 update","volume":"8","author":"Bays","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.aohep.2022.100738_bib0038","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jhep.2014.08.036","article-title":"Effects of n-3 fish oil on metabolic and histological parameters in NASH\u2013A double-blind, randomized, placebo-controlled trial","volume":"62","author":"Argo","year":"2015","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2022.100738_bib0039","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1185\/030079906X104696","article-title":"Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome\u2013A randomised study","volume":"22","author":"Athyros","year":"2006","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.1016\/j.aohep.2022.100738_bib0040","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0168-8278(99)80243-8","article-title":"A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis","volume":"31","author":"Basaranoglu","year":"1999","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2022.100738_bib0041","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.2337\/dc09-1765","article-title":"Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet","volume":"33","author":"Chan","year":"2010","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.aohep.2022.100738_bib0042","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/MCG.0000000000000099","article-title":"Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis","volume":"49","author":"Dasarathy","year":"2015","journal-title":"J Clin Gastroenterol"},{"issue":"22","key":"10.1016\/j.aohep.2022.100738_bib0043","doi-asserted-by":"crossref","first-page":"7008","DOI":"10.3748\/wjg.v21.i22.7008","article-title":"Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis","volume":"21","author":"Li","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.aohep.2022.100738_bib0044","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/hep.27647","article-title":"Ezetimibe for the treatment of nonalcoholic steatohepatitis\u2013Assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)","volume":"61","author":"Loomba","year":"2015","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"2","key":"10.1016\/j.aohep.2022.100738_bib0045","first-page":"92","article-title":"Rosuvastatin reduces nonalcoholic fatty liver disease in patients with chronic hepatitis C treated with \u03b1-interferon and ribavirin\u2013Rosuvastatin reduces NAFLD in HCV patients","volume":"11","author":"Malaguarnera","year":"2011","journal-title":"Hepat Mon"},{"issue":"10","key":"10.1016\/j.aohep.2022.100738_bib0046","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/MCG.0b013e31819c392e","article-title":"A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis\u2013A randomized placebo-controlled trial","volume":"43","author":"Nelson","year":"2009","journal-title":"J Clin Gastroenterol"},{"issue":"7","key":"10.1016\/j.aohep.2022.100738_bib0047","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133496","article-title":"Fish oil supplements lower serum lipids and glucose in correlation with a reduction in plasma fibroblast growth factor 21 and prostaglandin E2 in nonalcoholic fatty liver disease associated with hyperlipidemia\u2013A randomized clinical trial","volume":"10","author":"Qin","year":"2015","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.aohep.2022.100738_bib0048","first-page":"OC19","article-title":"Comparative effect of insulin sensitizers and statin on metabolic profile and ultrasonographical score in non alcoholic fatty liver disease","volume":"10","author":"Rana","year":"2016","journal-title":"J Clin Diagn Res"},{"key":"10.1016\/j.aohep.2022.100738_bib0049","first-page":"1","article-title":"Flaxseed oil in the context of a weight loss program ameliorates fatty liver grade in patients with non-alcoholic fatty liver disease\u2013A randomized double-blind controlled trial","author":"Rezaei","year":"2020","journal-title":"Br J Nutr"},{"issue":"4","key":"10.1016\/j.aohep.2022.100738_bib0050","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/hep.27289","article-title":"Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease\u2013Results from the Welcome* study","volume":"60","author":"Scorletti","year":"2014","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.aohep.2022.100738_bib0051","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4103\/jrms.JRMS_282_18","article-title":"A randomized controlled trial comparing effects of a low-energy diet with n-3 polyunsaturated fatty acid supplementation in patients with non-alcoholic fatty liver disease","volume":"24","author":"Shojasaadat","year":"2019","journal-title":"J Res Med Sci"},{"issue":"8","key":"10.1016\/j.aohep.2022.100738_bib0052","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3109\/09637486.2010.487480","article-title":"Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients\u2013A preliminary study","volume":"61","author":"Sofi","year":"2010","journal-title":"Int J Food Sci Nutr"},{"issue":"3","key":"10.1016\/j.aohep.2022.100738_bib0053","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.dld.2007.10.003","article-title":"Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease","volume":"40","author":"Spadaro","year":"2008","journal-title":"Dig Liver Dis"},{"issue":"5","key":"10.1016\/j.aohep.2022.100738_bib0054","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s00125-013-3149-9","article-title":"The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism\u2013A randomised controlled trial","volume":"57","author":"Takeshita","year":"2014","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.aohep.2022.100738_bib0055","doi-asserted-by":"crossref","DOI":"10.3390\/nu10081126","article-title":"Evaluation of a high concentrate omega-3 for correcting the omega-3 fatty acid nutritional deficiency in non-alcoholic fatty liver disease (CONDIN)","volume":"10","author":"Tobin","year":"2018","journal-title":"Nutrients"},{"issue":"12","key":"10.1016\/j.aohep.2022.100738_bib0056","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1097\/MEG.0000000000000981","article-title":"Comparison of fenofibrate and pioglitazone effects on patients with nonalcoholic fatty liver disease","volume":"29","author":"Yaghoubi","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"41","key":"10.1016\/j.aohep.2022.100738_bib0057","doi-asserted-by":"crossref","first-page":"6395","DOI":"10.3748\/wjg.14.6395","article-title":"Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia","volume":"14","author":"Zhu","year":"2008","journal-title":"World J Gastroenterol"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268122000801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268122000801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:45:03Z","timestamp":1761648303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268122000801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1665268122000801"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2022.100738","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of dyslipidemia treatment in NAFLD patients: a meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2022.100738","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"100738"}}